WCN26-5558 EFFICACY AND SAFETY OF HSK39297, A ONCE-DAILY ORAL CFB INHIBITOR, IN PATIENTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL

Conclusion:Long-term, low-dose phosphorus loading induces significant metabolic alterations and reduced lifespan without hyperphosphatemia, with sex-specific manner likely influenced by sex hormones.Our experimental models provide new insights into the sexspecific outcomes observed in chronic kidney disease patients, who are particularly susceptible to phosphorus dysregulation.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.